<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="COLON CANCER tet
Epidemiology  ~135000 estimated annual new cases of CRC in US in 2016: 95000 colon, 39000 rectal ~49,000 annual deaths, accounting for 8."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle="><title>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.440c12afe56c47722e71383f56d9f8f0.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.9d824aa930866f2c31941e3db882301d.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Sep 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/CRC.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><a href=#epidemiology>Epidemiology</a></li><li><a href=#risk-factors>Risk Factors</a><ol><li><a href=#other-associations>Other associations</a></li></ol></li><li><a href=#prevention>Prevention</a><ol><li><a href=#asa--nsaids>ASA & NSAIDs</a></li><li><a href=#diet>Diet</a></li></ol></li><li><a href=#pathology>Pathology</a><ol><li><a href=#adenoma-ca-sequence>Adenoma-CA sequence</a></li><li><a href=#serrated-polyp-pathway-cpg-island-methylation-phenotype-or-cimp>Serrated polyp pathway (CpG Island Methylation Phenotype or CIMP)</a></li></ol></li><li><a href=#molecular-classification>Molecular Classification</a><ol><li><a href=#cimp-serrated-polyp-pathway>CIMP (serrated polyp pathway)</a></li><li><a href=#lynch-hereditary-2-to-mts-in-mmr-genes-mlh1-msh2-msh6-pms2-epcam>Lynch (hereditary, 2Â° to mts in MMR genes MLH1, MSH2, MSH6, PMS2, EPCAM)</a></li></ol></li><li><a href=#clinical-presentation>Clinical Presentation</a></li><li><a href=#screening-in-average-risk-populations>Screening in Average Risk Populations</a><ol><li><a href=#preferred-by-most-guidelines>Preferred by most guidelines</a></li><li><a href=#other-options>Other options</a></li></ol></li><li><a href=#screening-in-increased-risk-populations-see-lynchfap-chapter-diagnostic-evaluation>Screening in Increased Risk Populations (See Lynch/FAP chapter) Diagnostic Evaluation</a></li><li><a href=#staging-and-prognosis>Staging and Prognosis</a></li><li><a href=#surveillance-after-initial-therapy>Surveillance After Initial Therapy</a></li><li><a href=#chemotherapy-for-advanced-and-metastatic-disease>Chemotherapy for Advanced and Metastatic Disease</a><ol><li><a href=#definitions>Definitions</a></li><li><a href=#1st-line>1st line</a></li><li><a href=#2nd-line>2nd line</a></li><li><a href=#3rd-line>3rd line</a></li></ol></li></ol></nav></details></aside><a href=#colon-cancer><h1 id=colon-cancer><span class=hanchor arialabel=Anchor># </span>COLON CANCER</h1></a><p><code>tet</code></p><a href=#epidemiology><h2 id=epidemiology><span class=hanchor arialabel=Anchor># </span>Epidemiology</h2></a><ul><li>~135000 estimated annual new cases of CRC in US in 2016: 95000 colon, 39000 rectal</li><li>~49,000 annual deaths, accounting for 8.3% of all CA death
Highest incidence in Australia & New Zealand, Europe & North America</li></ul><a href=#risk-factors><h2 id=risk-factors><span class=hanchor arialabel=Anchor># </span>Risk Factors</h2></a><ul><li>Age, increasing incidence w/ age w/ relative rise starting at age 40â€“50</li><li>Familial syn (FAP, Lynch, MUTYH-associated polyposis, Peutzâ€“Jeghers, Juvenile polyposis) (see Lynch/FAP chapter)</li><li>Personal or FHx of CRC or adenomatous polyps</li><li>IBD: UC > CD, increasing risk 8â€“10 y after initial dx</li></ul><hr><a href=#other-associations><h3 id=other-associations><span class=hanchor arialabel=Anchor># </span>Other associations</h3></a><ul><li>high red meat intake,</li><li>diabetes,</li><li>long-term immunosuppression,</li><li>EtOH, tobacco;</li><li>although classically thought to be a risk factor, prospective studies have not clearly demonstrated an association between low dietary fiber intake & colon CA (JAMA 2005, 294:2849)</li></ul><a href=#prevention><h2 id=prevention><span class=hanchor arialabel=Anchor># </span>Prevention</h2></a><a href=#asa--nsaids><h3 id=asa--nsaids><span class=hanchor arialabel=Anchor># </span>ASA & NSAIDs</h3></a><ul><li>Potential protective effect of ASA & NSAIDs on development of colonic adenomas & CRC</li></ul><a href=#diet><h3 id=diet><span class=hanchor arialabel=Anchor># </span>Diet</h3></a><ul><li>Potential protective benefit of avoidance of red meat, limited caloric intake</li></ul><a href=#pathology><h2 id=pathology><span class=hanchor arialabel=Anchor># </span>Pathology</h2></a><a href=#adenoma-ca-sequence><h3 id=adenoma-ca-sequence><span class=hanchor arialabel=Anchor># </span>Adenoma-CA sequence</h3></a><p>Most common pathway, adenomas on avg take 10 y to develop (Cell 1990;61:759). Accumulation of genetic mts (eg, APC: TP53) leads to tumorigenesis; risk of CRC â†‘ w/ adenoma size, #, & histology (villous > tubular)</p><a href=#serrated-polyp-pathway-cpg-island-methylation-phenotype-or-cimp><h3 id=serrated-polyp-pathway-cpg-island-methylation-phenotype-or-cimp><span class=hanchor arialabel=Anchor># </span>Serrated polyp pathway (CpG Island Methylation Phenotype or CIMP)</h3></a><p>Alternative route for CRC development through serrated adenomas</p><a href=#molecular-classification><h2 id=molecular-classification><span class=hanchor arialabel=Anchor># </span>Molecular Classification</h2></a><ul><li>Chromosomal instability (hereditary & sporadic): Gain of function mts in oncogenes (eg, KRAS, & loss of function mts in tumor suppressor genes (eg, APC, TP53, DCC, SMAD4, SMAD2), no MSI</li></ul><blockquote><p>quote</p></blockquote><hr><a href=#cimp-serrated-polyp-pathway><h3 id=cimp-serrated-polyp-pathway><span class=hanchor arialabel=Anchor># </span>CIMP (serrated polyp pathway)</h3></a><ul><li>Hypermethylation of promoters of MMR genes such as MLH1 & tumor suppressors, mutational inactivation of genes w/ microsatellites (eg, BAX, TGF-Î²IIR), high incidence of BRAF mutants, MSI-high tumors</li></ul><a href=#lynch-hereditary-2-to-mts-in-mmr-genes-mlh1-msh2-msh6-pms2-epcam><h3 id=lynch-hereditary-2-to-mts-in-mmr-genes-mlh1-msh2-msh6-pms2-epcam><span class=hanchor arialabel=Anchor># </span>Lynch (hereditary, 2Â° to mts in MMR genes MLH1, MSH2, MSH6, PMS2, EPCAM)</h3></a><ul><li>MSI-high, (â€“)chromosomal instability, (â€“)BRAF mutant</li></ul><a href=#clinical-presentation><h2 id=clinical-presentation><span class=hanchor arialabel=Anchor># </span>Clinical Presentation</h2></a><ul><li>Sx are generally nonspecific & many pts are asx until advanced disease</li><li>Distal colon: hematochezia, abdominal pain, obstruction, overflow diarrhea</li><li>Proximal colon: Fe deficiency anemia, melena, hematochezia, obstruction (rare)</li><li>Met disease: RUQ pain, ascites, wt loss, fatigue</li><li>Other sx: Sx from local invasion (bladder, small bowel); may mimic diverticulitis; FUO; S. bovis bacteremia & C. septicum sepsis</li></ul><a href=#screening-in-average-risk-populations><h2 id=screening-in-average-risk-populations><span class=hanchor arialabel=Anchor># </span>Screening in Average Risk Populations</h2></a><a href=#preferred-by-most-guidelines><h3 id=preferred-by-most-guidelines><span class=hanchor arialabel=Anchor># </span>Preferred by most guidelines</h3></a><p>Colonoscopy every 5â€“10 y starting at 50, highest Se & Sp, â†“ mortality in RCT (NEJM 2012;366:687); screening past 85 not typically recommended or if the individual has serious medical comorbidities</p><a href=#other-options><h3 id=other-options><span class=hanchor arialabel=Anchor># </span>Other options</h3></a><p>CT colonography every 5 y; flexible sigmoidoscopy every 5 y; FOBT annually; fecal immunochemical test (FIT) annually; stool DNA (optimal interval uncertain)</p><a href=#screening-in-increased-risk-populations-see-lynchfap-chapter-diagnostic-evaluation><h2 id=screening-in-increased-risk-populations-see-lynchfap-chapter-diagnostic-evaluation><span class=hanchor arialabel=Anchor># </span>Screening in Increased Risk Populations (See Lynch/FAP chapter) Diagnostic Evaluation</h2></a><ul><li>Colonoscopy</li><li>CT of chest abdomen & pelvis</li><li>Hepatic function panel, CEA</li><li>KRAS/NRAS/BRAF mutant status only in pts w/ met dz</li><li>MSI testing or IHC for MMR proteins for all pts</li></ul><a href=#staging-and-prognosis><h2 id=staging-and-prognosis><span class=hanchor arialabel=Anchor># </span>Staging and Prognosis</h2></a><ul><li>Right-sided tumors generally have a worse prognosis</li></ul><p><img src=https://i.imgur.com/zoAZmtW.png width=auto alt=" h:400"></p><a href=#surveillance-after-initial-therapy><h2 id=surveillance-after-initial-therapy><span class=hanchor arialabel=Anchor># </span>Surveillance After Initial Therapy</h2></a><ul><li>Hx & physical & CEA every 6 mos for 5 y</li><li>CT of chest/abd/pelvis annually for 5 yâ€”no role for PET scans</li><li>Colonoscopy in 1 y;<ul><li>if no adv adenoma repeat in 3 y, then every 5 y</li></ul></li></ul><a href=#chemotherapy-for-advanced-and-metastatic-disease><h2 id=chemotherapy-for-advanced-and-metastatic-disease><span class=hanchor arialabel=Anchor># </span>Chemotherapy for Advanced and Metastatic Disease</h2></a><a href=#definitions><h3 id=definitions><span class=hanchor arialabel=Anchor># </span>Definitions</h3></a><a href=#folfox---infusional-5-fulv--ox><h4 id=folfox---infusional-5-fulv--ox><span class=hanchor arialabel=Anchor># </span>FOLFOX: - Infusional 5-FU/LV + OX</h4></a><a href=#folfiri-infusional-5-fulv--irinotecan><h4 id=folfiri-infusional-5-fulv--irinotecan><span class=hanchor arialabel=Anchor># </span>FOLFIRI: Infusional 5-FU/LV + irinotecan</h4></a><a href=#folfoxiri-infusional-5-fulv--ox--irinotecan><h4 id=folfoxiri-infusional-5-fulv--ox--irinotecan><span class=hanchor arialabel=Anchor># </span>FOLFOXIRI: Infusional 5-FU/LV + OX + irinotecan</h4></a><a href=#capeox-cape--ox><h4 id=capeox-cape--ox><span class=hanchor arialabel=Anchor># </span>CapeOX Cape: + OX</h4></a><hr><a href=#1st-line><h3 id=1st-line><span class=hanchor arialabel=Anchor># </span>1st line</h3></a><p>Infusional 5-FU/LV; Cap; FOLFOX (JCO 2004;22:23); CapeOX; FOLFIRI (JCO 2007;25:4779) Â± Bev (JCO 2008;26:2013); FOLFOX or FOLFIRI Â± cetuximab/panitumumab (CRYSTAL NEJM 2009;360:1408; JCO 2010;28:4697), FOLFOXIRI Â± Bev (TRIBE NEJM 2014; 371:1609)</p><hr><a href=#2nd-line><h3 id=2nd-line><span class=hanchor arialabel=Anchor># </span>2nd line</h3></a><p>FOLFIRI or irinotecan for pts who received prior FOLFOX; FOLFOX/CapeOX for pts w/ prior FOLFIRI; FOLFOX/CapeOX, or FOLFIRI for prior 5-FU/LV or Cap; all regimens Â± Bev/ziv-aflibercept/ramucirumab (note that ramucirumab use is discouraged due to higher cost w/o improved efficacy), irinotecan-based regimens Â± panitumumab/cetuximab</p><hr><a href=#3rd-line><h3 id=3rd-line><span class=hanchor arialabel=Anchor># </span>3rd line</h3></a><p>Irinotecan Â± panitumumab/cetuximab (BOND NEJM 2004; 351:337) or single agent panitumumab/cetuximab, or single-agent regorafenib or TAS-102
Overall benefits of regorafenib or TAS-102 are modest w/ significant s/e
For FOLFOX, OX can be discontinued after 3â€“4 mos of Rx till progression to avoid neurotoxicity (OPTIMOX1 JCOl 2006;24:394)</p><hr><ul><li>Do not use anti-EGFR Rx in RAS mutant CAs; also likely ineffective in BRAF mutants</li><li>Do not use dual Ab (anti-EGFR & anti-VEGF) Rx (CAIRO2 NEJM 2009;360:563)
Right-sided CRC have poor prognosis & anti-EGFR Rx is ineffective even if RAS WT (JCO 2016;34 (suppl, abstr 3504, 3505, 3506), JAMA Oncol 2017;3:211).</li><li>MSI-H predicts response to PD-1 blockade (NEJM 2015;372:2509)</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>